Vanda Pharmaceuticals (VM4) Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
VM4 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Vanda Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.65 |
| 52 Week High | US$7.60 |
| 52 Week Low | US$3.46 |
| Beta | 0.60 |
| 1 Month Change | 46.48% |
| 3 Month Change | 46.48% |
| 1 Year Change | 45.83% |
| 3 Year Change | -2.92% |
| 5 Year Change | -43.64% |
| Change since IPO | -13.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| VM4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 6.4% | 4.0% | 1.5% |
| 1Y | 45.8% | -34.7% | 14.1% |
Return vs Industry: VM4 exceeded the German Biotechs industry which returned -30.1% over the past year.
Return vs Market: VM4 exceeded the German Market which returned 14.5% over the past year.
Price Volatility
| VM4 volatility | |
|---|---|
| VM4 Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: VM4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: VM4's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 368 | Mihael Polymeropoulos | www.vandapharma.com |
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis.
Vanda Pharmaceuticals Inc. Fundamentals Summary
| VM4 fundamental statistics | |
|---|---|
| Market cap | €397.84m |
| Earnings (TTM) | -€72.02m |
| Revenue (TTM) | €181.41m |
Is VM4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VM4 income statement (TTM) | |
|---|---|
| Revenue | US$212.07m |
| Cost of Revenue | US$11.80m |
| Gross Profit | US$200.27m |
| Other Expenses | US$284.47m |
| Earnings | -US$84.20m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.42 |
| Gross Margin | 94.44% |
| Net Profit Margin | -39.70% |
| Debt/Equity Ratio | 0% |
How did VM4 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 09:43 |
| End of Day Share Price | 2026/01/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vanda Pharmaceuticals Inc. is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Olivia Brayer | BofA Global Research |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |